Ronald Muhlenkamp
Muhlenkamp & Co
Ronald Muhlenkamp Epizyme Inc stake
total: 197
Muhlenkamp & Co EPZM trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2015 Q1
- Held for:
- 4 quarters
- Latest activity:
- 2016 Q1
According to 2026 Q2 report, Ronald Muhlenkamp doesn't hold any Epizyme Inc (EPZM) shares. To date, the estimated cost basis is nearly $18.72 for "buy" trades and estimated average "sell" price is $16.02. Muhlenkamp & Co first purchased EPZM in 2015 Q1, initially acquiring 51,860 shares. Since the initial investment in Epizyme Inc (EPZM), Muhlenkamp & Co has made 3 more transactions.
When did Ronald Muhlenkamp sell Epizyme Inc (EPZM)?
Ronald Muhlenkamp sold off the entire Epizyme Inc (EPZM) position in 2016 Q1.
When did Ronald Muhlenkamp buy Epizyme Inc (EPZM)?
Ronald Muhlenkamp first invested in Epizyme Inc (EPZM) in 2015 Q1 at the reported quarter-end price of $18.78 per share.
What's the cost basis of Muhlenkamp & Co's EPZM stake?
The estimated cost basis for Epizyme Inc (EPZM) stake is around $18.72 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $18.72
- Weighted AVG sell price:
- $16.02
Ronald Muhlenkamp's historical trades in Epizyme Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2016 Q1
|
0.00%
|
$16.02
|
-100% (-50,000)
|
|||
|
2015 Q4
|
0.25%
|
$16.02
|
-4.53% (-2,370)
|
|||
|
2015 Q3
|
0.21%
|
$12.85
|
+0.98% (+510)
|
|||
|
2015 Q1
|
0.21%
|
$18.78
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.